

## Davidson, Mark

---

**From:** Davidson, Mark  
**Sent:** Tuesday, October 17, 2017 4:08 PM  
**To:** 'Rizwana Sproule'  
**Cc:** 'Alex Babayan'; 'Nadia Agopyan'  
**Subject:** Kite Pharma 125643 YESCARTA PRESCRIBING INFORMATION Label 10.17.17  
**Attachments:** YESCARTA PI Working Version 10.17.17.Final.docx

**Importance:** High

Dear Dr. Sproule,

Please see the attached prescribing Information (PI) label for YESCARTA™ (axicabtagene ciloleucel). This is the final revision to the prescribing information label. Please review and **return the PI back to me by Today, Tuesday 10.17.17**. In your return email, agree with **all** recommended changes to complete the PI review process. Particularly, review all the greater than or equal signs to make sure that they are consistent through the document. Send back via email one track copy and one clean copy of the PI. Afterwards, submit immediately to the gateway as a formal amendment to BLA 125643. Please give me a call if you have questions.

Thank You

Mark L. Davidson, RHIA  
Regulatory Project Manager  
OTAT/CBER/FDA  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002  
Phone: 240-402-8277  
Fax:301-595-1303  
[mark.davidson@fda.hhs.gov](mailto:mark.davidson@fda.hhs.gov)

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."